Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI

Journal of Neuro-Oncology

Volumn 46, Issue 3, 2000, Pages 249-259

  Vlassenko, Andrei G ^a   Thiessen, Brian ^a   Beattie, Bradley J ^a   Malkin, Mark G ^a   Blasberg, Ronald G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

18F 2 fluoro 2 deoxyglucose; Anaplastic astrocytoma; Glioblastoma multiforme; Magnetic resonance imaging; Positron emission tomography; SU101

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE MEGLUMINE; LEFLUNOMIDE;

ADULT; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; DRUG MONITORING; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; BIOLOGICAL TRANSPORT, ACTIVE; CARMUSTINE; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENERGY METABOLISM; FEMALE; FLUORODEOXYGLUCOSE F18; GADOLINIUM DTPA; GLIOBLASTOMA; GLUCOSE; HUMANS; ISOXAZOLES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PLATELET-DERIVED GROWTH FACTOR; PROGNOSIS; SIGNAL TRANSDUCTION; SUPRATENTORIAL NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0034085545     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006481313747     Document Type: Article

References (43)

1. Shawver LK, Schwartz DP, Mann E, et al.: Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[(4-trifluoromethyl)-phenyl]-5-methylisoxazole-4-carboxamide. Clin Cancer Res 3: 1167-1177, 1997
2. Williams LT: Signal transduction by the platelet-derived growth factor. Science 243: 1564-1570, 1989
3. Habenicht AJR, Salbach P, JanBen-Timmen U, Blattner C, Schettler G: Platelet-derived growth-factor - alpha growth factor with an expanding role in health and disease. Klin Wochenschr 68: 53-59, 1990
4. Plowman G, Ullrich A, Shawver LK: Receptor tyrosine kinases as targets for drug intervention. Drug News and Perspective 7: 334-339, 1994
5. Cherwinski HM, Byars N, Ballaron SJ, Nakano GM, Young JM, Ranson JT: Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm Res 44: 317-322, 1995
6. Davis JP, Cain GA, Pitts WJ, Magdola RL, Copeland RA: The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 35: 1270-1273, 1996
7. Malkin MG, Mason WP, Lieberman FS, et al.: Phase I study of SU101, a novel signal transduction inhibitor, in recurrent malignant glioma. Proc Amer Soc Clin Oncol 16: 385a, 1997
8. Malkin MG, Rosen L, Lopez AM, et al.: Phase 2 study of SU101, a PDGF-R signal transduction inhibitor, in recurrent malignant glioma. Proc Amer Soc Clin Oncol 17: 390a, 1998
9. Earnest F, Kelly PJ, Scheithauer BW, et al.: Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 166: 823-827, 1988
10. Di Chiro G: Positron emission tomography using [18F]fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 22: 360-371, 1987
11. Elster AD, Di Presio DA: Cranial postoperative site: assessment with contrast-enhanced MR imaging. Radiology 174: 93-98, 1990
12. Di Chiro G, Oldfield E, Wright DC, et al.: Cerebral necrosis after radiotherapy and/or intra-arterial chemotherapy for brain tumors: PET and neuropathologic studies. AJNR 8: 1083-1091, 1987
13. Alavi JB, Alavi A, Chawluk J, Kushner M, Powe J, Hickey W, Reivich M: Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 62: 1074-1078, 1988
14. Delbeke D, Meyerowitz C, Lapidus RL, Maciunas RJ, Jennings MT, Moots PL, Kessler RM: Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 195: 47-52, 1995
15. 18F]2-fluoro-2-deoxyglucose-positron emission tomography correlation of gadolinium-enhanced MR imaging of central nervous system neoplasia. AJNR 14: 515-523, 1993
16. Gross MW, Weber WA, Feldmann HJ, Bartenstein P, Schwaiger M, Molls M: The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys 41: 989-995, 1998
17. Olivero WC, Dulebohn SC, Lister JR: The use of PET in evaluating patients with primary brain tumors: is it useful? J Neurol Neurosurg Psychiatry 57: 250-252, 1995
18. Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP: Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR 19: 407-413, 1998
19. Hamacher K , Coenen HH , Stocklin G: Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27(2): 235-238, 1986
20. Collignon A, Maes F, Delaere D, Vandermeulen D, Suetens P, Marchal G: Automated multi-modality image registration based on information theory. In: Bizais Y, Barillot C, Di Paola R (eds) Information Processing in Medical Imaging 1995. Kluwer Academic Publishers, Dordrecht, 1995, pp 263-274
21. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H: Influence of the blood glucose concentration on FDG uptake in cancer: a PET study. J Nucl Med 34: 1-6, 1993
22. Kim CK, Gupta NC, Chandramouli B, Alavi A: Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med 35: 164-167, 1994
23. 11C]Tyrosine PET. J Nucl Med 38: 692-696, 1997
24. Di Chiro G, DeLaPaz RL, Brooks RA: Glucose utilization of cerebral gliomas measured by [18]fluorodeoxyglucose and positron emission tomography. Neurology 32: 1323-1329, 1982
25. Patronas NJ, Di Chiro G, Kufta C, Bairamian D, Kornblith PL, Simon R, et al.: Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 62: 816-822, 1985
26. Mineura K, Yasuda T, Kowada M, Ogawa T, Shishido F, Uemura K: Positron emission tomographic evaluation of radiochemotherapeutic effect on regional cerebral hemocirculation and metabolism in patients with gliomas. J Neuro-Oncol 5: 277-285, 1987
27. Phillips PC, Dhawan V, Strother SC, Sidtis JJ, Evans AC, Allen JC, Rottenberg DA: Reduced cerebral glucose metabolism and increased brain capillary permeability following high-dose methotrexate chemotherapy: a positron emission tomographic study. Ann Neurol 21: 59-63, 1987
28. Ogawa T, Uemura K, Shishido F, Yamaguchi T, Murakami M, Inugami A, Kanno I, Sasaki H, Kato T, Hirata K, Kowada M, Mineura K, Yasuda T: Changes of cerebral blood flow, and oxygen and glucose metabolism following radiochemotherapy of gliomas: a PET study. J Comput Assist Tomogr 12: 290-297, 1988
29. Barker FG, Chang SM, Valk PE, Pounds TR, Prados MD: 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 79: 115-126, 1997
30. Janus TJ, Kim EE, Tilbury R, Bruner JM, Yung WK: Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 33: 540-548, 1993
31. Schifter T, Hoffman JM, Hanson MW, Boyko OB, Beam C, Paine S, et al.: Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors. J Comput Assist Tomogr 17: 509-516, 1993
32. Kahn D, Follett KA, Bushnell DL, Nathan MA, Piper JG, MadsenM, etal.: Diagnosis of recurrent brain tumor: value of 201T1 SPECT vs 18F-fluorodeoxyglucose PET. Am J Roentgenol 163: 1459-1465, 1994
33. Langen KJ, Roosen N, Kuwert T, Herzog H, Kiwit JC, Rota-Kops E, etal.: Early effects of intra-arterial chemotherapy in patients with brain tumors studied with PET: preliminary results. Nucl Med Commun 10: 779-790, 1989
34. Holzer T, Herholz K, Jeske J, Heiss WD: FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J Comput Assist Tomogr 17: 681-687, 1993
35. Haberkorn U, Strauss LG, Dimitrakopoulou A, Seiffert E, Oberdorfer F, Ziegler S, Reisser C, Doll J, Helus F, van Kaick G: Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 34: 12-17, 1993
36. DeWitte O, Hildebrand J, Luxen A, Goldman S: Acute effect of carmustine on glucose metabolism in brain and glioblastoma. Cancer 74: 2836-2842, 1994
37. Rozental JM, Levine RL, Nickles RJ, Dobkin JA: Glucose uptake by gliomas after treatment: a positron emission tomographic study. Arch Neurol 46: 1302-1307, 1989
38. Rozental JM, Cohen JD, Mehta MP, Levine RL, Hanson JM, Nickles RJ: Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. J Neuro-Oncol 15: 57-66, 1993
39. Wang L, Hayashi H, Ebina Y: Transient effect of platelet-derived growth factor on GLUT4 translocation in 3T3-L1 adipocytes. J Biol Chem 274: 19 246-19 253, 1999
40. Conricode KM: Involvement of phosphatidylinositol 3-kinase in stimulation of glucose transport by growth factors in 3T3-L1 adipocytes. Biochem Mol Biol Int 36: 835-843, 1995
41. Kamohara S, Hayashi H, Todaka M, et al.: Platelet-derived growth factor triggers translocation of the insulin-regulatable glucose transporter (type 4) predominantly through phosphatidylinositol 3-kinase binding sites on the receptor. Proc Natl Acad Sci USA 92: 1077-1081, 1995
42. Plate KH, Breier G, Farrell CL, Risau W: Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab Invest 67: 529-534, 1992
43. Strawn LM, Mann E, Elliger SS, et al.: Inhibition of glioma by a truncated platelet-derived growth factor-beta receptor. J Biol Chem 269: 21 215-21 222, 1994